Download PDF
Thromb Haemost 1969; 22(01): 035-044
DOI: 10.1055/s-0038-1651327
Originalarbeiten-Original Articles-Travaux Originaux
Schattauer GmbH

Sensitivity of Pregnant Mice to Intravenous Tissue Thromboplastin

S Coccheri   *
1   The James F. Mitchell Foundation, Institute for Medical Research, Washington, D.C., 20015, U.S.A.
,
P Ollendorff   **
1   The James F. Mitchell Foundation, Institute for Medical Research, Washington, D.C., 20015, U.S.A.
,
T Astrup
1   The James F. Mitchell Foundation, Institute for Medical Research, Washington, D.C., 20015, U.S.A.
› Author AffiliationsSupported by Grant HE-05020 from the U. S. Public Health Service, National Institutes of Health, National Heart Institute, and by a grant-in-aid from the Warner-Lambert Research Institute.
Further Information

Publication History

Publication Date:
10 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

Pregnant mice are more susceptible to the intravenous injection of tissue thromboplastin than nonpregnant mice. This was true whether death of the animal, or the appearance of neurological symptoms, was used as indicator of toxicity. Increase of fibrinogen concentration or prior injection of plasmin or of a protease inhibitor (trypsin inhibitor from bovine lung) did not influence the immediate toxic effects. The reason for the increased sensitivity of pregnant mice to tissue thromboplastin remains undisclosed. Inhibition of tissue thromboplastin by serum is a slow process. The reported increase in inhibition of tissue thromboplastin by serum from pregnant individuals could not be confirmed.

* Present address : Institute of Occupational Medicine, University of Bologna, Italy. Recipient of a Fulbright travel grant on leave of absence from the University of Bologna.


** Present address: Glostrup Hospital, Medical Department F, Glostrup, Denmark. Recipient of a Fulbright travel grant, of a research stipend from the University of Copenhagen, and of a grant from the P. Carl Petersen Foundation.


 

  • References

  • 1 Albrechtsen O. K, Brakman P, Astrup T. Effects of intravenous tissue thromboplastin in pregnant rabbits. In preparation.
    PubMed
  • 2 Astrup T. Assay and content of tissue thromboplastin in different organs. Thrombos. Diathes. haemorrh. (Stuttg.) 14: 401 1965;
    PubMedSearch in Google Scholar
  • 3 Astrup T, Albrechtsen O. K. Serum effects following tissue thromboplastin infusion. Thrombos. Diathes. haemorrh. (Stuttg.) 21: 111 1969;
    PubMedSearch in Google Scholar
  • 4 Astrup T, Stage A. A protease inhibitor in ox lung tissue. Acta chem. scand. 10: 617 1956;
    CrossrefPubMedSearch in Google Scholar
  • 5 Brakman P. The fibrinolytic system in human blood during pregnancy. Amer. J. Obstet. Gynec. 94: 14 1966;
    CrossrefPubMedSearch in Google Scholar
  • 6 Brakman P, Astrup T. Selective inhibition inhuman pregnancy blood of urokinase induced fibrinolysis. Scand. J. clin. Lab. Invest. 15: 603 1963;
    CrossrefPubMedSearch in Google Scholar
  • 7 Breckenridge R. T, Ratnoff O. D. Pulmonary embolism and unexpected death in supposedly normal persons. New Engl. J. Med. 270: 298 1964;
    CrossrefPubMedSearch in Google Scholar
  • 8 Goldbarg A. N, Hellerstein H. K, Bruell J. H, Daroczy A. F. Electrocardiogram of the normal mouse, mus musculus: General considerations and genetic aspects. Cardiovasc. Res. 2: 93 1968;
    CrossrefPubMedSearch in Google Scholar
  • 9 Hardaway III R. M. Syndromes of Disseminated Intravascular Coagulation. Charles C. Thomas; Springfield, Illinois,: 1966
    Search in Google Scholar
  • 10 Heřmanský F, Vitek J. The role of proconvertin and Stuart Factor in the inactivation of tissue thromboplastin by serum. Experientia (Basel) 16: 455 1960;
    CrossrefPubMedSearch in Google Scholar
  • 11 Hjort P. F. Intermediate reactions in the coagulation of blood with tissue thromboplastin: convertin, accelerin, prothrombinase. Scand. J. clin. Lab. Invest.. 9, Suppl. 27 1957
    PubMedSearch in Google Scholar
  • 12 Lanchantin G. F, Ware A. G. Identification of a thromboplastin inhibitor in serum and in plasma. J. clin. Invest. 32: 381 1953;
    CrossrefPubMedSearch in Google Scholar
  • 13 McKay D. G. Disseminated Intravascular Coagulation. An Intermediary Mechanism of Disease. Hoeber Medical Division. Harper and Row; New York, N. Y.: 1965
    Search in Google Scholar
  • 14 Obata I. On the nature of eclampsia. J. Immunol. 4: 111 1919;
    PubMedSearch in Google Scholar
  • 15 Pechet L, Alexander B. Increased clotting factors in pregnancy. New Engl. J. Med. 265: 1093 1961;
    CrossrefPubMedSearch in Google Scholar
  • 16 Schneider C. L. The inactivation of placental toxin by human serum. Amer. J. Physiol. 147: 140 1946;
    PubMedSearch in Google Scholar
  • 17 Schneider C. L. Placental toxin: Inactivation and tolerance during pregnancy. Amer. J. Physiol. 147: 255 1946;
    PubMedSearch in Google Scholar
  • 18 Schneider G. L. The active principle of placental toxin: Thromboplastin and its inactivator in blood: antithromboplastin. Amer. J. Physiol. 149: 123 1947;
    PubMedSearch in Google Scholar
  • 19 Thomas L. Studies on intravascular thromboplastic effect of tissue suspensions in mice. I) Reaction of mice to intravenous injections of sedimentable tissue components. Bull. Johns Hopk. Hosp. 81: 1 1947;
    PubMedSearch in Google Scholar
  • 20 Thomas L. Studies on intravascular thromboplastic effect of tissue suspensions in mice. II) A factor in normal rabbit serum which inhibits the thromboplastic effect of the sedimentable tissue components. Bull. Johns Hopk. Hosp. 81: 26 1947;
    PubMedSearch in Google Scholar
  • 21 Tocantins L. M. Demonstration of antithromboplastic activity in normal and hemophilic plasmas. Amer. J. Physiol. 139: 265 1943;
    PubMedSearch in Google Scholar
  • 22 VillaSanta U. Thromboembolic disease in pregnancy. Amer. J. Obstet. Gynec. 93: 142 1965;
    CrossrefPubMedSearch in Google Scholar